Amylyx Pharmaceuticals Scheduled to Report Q3 2026 Earnings on November 5
Amylyx Pharmaceuticals (AMLX) is set to release its third-quarter 2026 financial results on Thursday, November 5, prior to the market opening. The company's performance will be evaluated against a consensus earnings per share (EPS) estimate of -$0.37 and a projected revenue of $0.04 million. Investors are closely monitoring these results as recent trends show shifts in EPS estimates over the preceding three-month period. Given the low revenue projections, the market focus will likely remain on cash burn rates and clinical development progress.
Tickers: $AMLX